Why the study?
Patients with ischemic heart failure on guideline-directed medical therapy still struggle with poor cardiac function and high readmission rates, making enhancement of cardiac function a critical challenge.
Does Qishen Yiqi dripping pills improve ejection fraction classification in patients with ischaemic heart failure on guideline-directed medical therapy?
Does Qishen Yiqi dripping pills improve ejection fraction classification in patients with ischaemic heart failure on guideline-directed medical therapy?
The addition of Qishen Yiqi dripping pills to guideline-directed medical therapy significantly improves ejection fraction classification and reduces adverse clinical events in patients with ischemic heart failure.
Answers are grounded in this paper and cite their sources.
May support adjunctive Qishen Yiqi in IHF on GDMT; hypothesis-generating and requires RCT confirmation before practice change.
• Even with the guideline-directed medical therapy (GDMT), patients with ischemic heart failure (IHF) still face a poor prognosis and endure a diminished quality of life. • In the context of GDMT, the Qishen Yiqi dripping pills have been observed to further facilitate the improvement in classification of ejection fraction in patients with IHF, enhance cardiac function, and improve quality of life. • The current study supported Qishen Yiqi dripping pills as a complementary therapy for patients with IHF, providing benefits to the restoration of cardiac function. This is particularly crucial for patients who have not achieved satisfactory results with GDMT. In patients with heart failure (HF), improved left ventricular ejection fraction (LVEF) classification is closely associated with increased survival rates. However, even patients receiving guideline-directed medical therapy (GDMT) still struggle with poor cardiac function and high rates of readmission. Enhancing cardiac function in HF patients and reducing the occurrence of adverse events (AEs) remain critical challenges at present. This study was designed to evaluate the effects of the Qishen Yiqi dripping pills (QSYQ) on the EF classification of patients with ischaemic HF (IHF). This is a secondary analysis of data from a multicentre, prospective cohort study involving 1,225 patients with IHF from 84 centres. We selected IHF patients with reduced (HFrEF) and mildly reduced (HFmrEF) EF. One-to-one propensity score matching (PSM) was performed to compare patients who received GDMT alone (control group) with patients who received additional treatment with QSYQ (QSYQ group). The primary outcome was the longitudinal improvement in EF at 90 days, defined as a change in EF classification from HFrEF to HFmrEF/HFpEF (HF with preserved EF) or from HFmrEF to HFpEF, with an increase in EF of at least 10 %. The secondary outcome was a composite endpoint consisting of all-cause mortality, hospitalization for HF, hospitalization for unstable angina, revascularization, nonfatal stroke, and malignant arrhythmias. Additionally, the New York Heart Association (NYHA) functional classification, Minnesota Living with Heart Failure Questionnaire (MLHFQ) scores, and safety were evaluated. Compared with the control treatment, the addition of QSYQ treatment for 90 days led to a 28 % increase in the improvement rate of EF classification in HFmEF or HFmrEF patients (RR: 1.28; 95 % CI: 1.03–1.59; p = 0.023), a 50 % reduction in the occurrence of composite endpoints (HR: 0.50; 95 % CI: 0.25–0.99; p = 0.04), a 40 % increase in the improvement rate of NYHA functional classification (RR: 1.40; 95 % CI: 1.26–1.55; p < 0.001), and a greater reduction in MLHFQ scores (-16.00 (-7.00, -27.00) vs. -8.00 (-1.00, -17.00), p < 0.001). Additionally, no increased risk of AEs was observed with the use of the QSYQ. As a complementary strategy in addition to HF guideline-directed treatments, QSYQ can further improve EF classification, reduce the occurrence rate of the composite endpoint, improve quality of life, and improve the safety profile of patients with IHF. The study protocol is registered with the Chinese Clinical Trial Registry (ChiCTR-ONRC-14,004,407).
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: